

---

# Kluwer Patent Blog

## Merck v. Teva, Commercial Court Antwerp (Rechtbank van Koophandel te Antwerpen), 20 October 2009

Florence Verhoestraete · Tuesday, October 20th, 2009 · Landmark European Patent Cases

The Antwerp Commercial Court dismissed Merck's claim for injunctive relief against Teva, ruling that Teva's montelukast-based generic medicines do not infringe Merck's European patent (EP 0 737 186) with respect to an improved process for preparation of the active ingredient montelukast, either literally or by equivalents.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

### Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT

The Wolters Kluwer Future Ready Lawyer  
Leading change

This entry was posted on Tuesday, October 20th, 2009 at 8:40 am and is filed under [Belgium](#), [Case Law](#), [Chemical Engineering](#), [Enforcement](#), [literally fulfil all features of the claim](#). The purpose of the doctrine is to prevent an infringer from stealing the benefit of an invention by changing minor or insubstantial details while retaining the same functionality. Internationally, the criteria for determining equivalents vary. For example, German courts apply a three-step test known as [Schneidmesser's questions](#). In the UK, the equivalence doctrine was most recently discussed in [Eli Lilly v Actavis UK](#) in July 2017. In the US, the function-way-result test is used.">Equivalents, Extent of Protection, Injunction, Scope of protection

You can follow any responses to this entry through the [Comments \(RSS\) feed](#). Both comments and pings are currently closed.